COVID 19 Impact on IVD (In Vitro Diagnostics) Market by Technology (PCR, NGS, ELISA, Rapid Test, Hematology, Hemostasis, Clinical Chemistry, Microbiology Testing, Urinalysis), End-user and Region - Global Forecast to 2025
“The global in-vitro diagnostics market is expected to be valued at USD 61.0 billion in 2020, growing at a CAGR of 6.5% during 2020-2025.”
The global in-vitro diagnostics market size is expected to be valued at USD 61.0 billion in 2020, growing at a CAGR of 6.5% during 2020-2025. The demand for in-vitro diagnostic products due to the COVID-19 pandemic is expected to increase mainly due to factors such as a sharp rise in market demand for PCR, NGS, serology based rapid-test products, the supportive regulatory landscape for product development & commercialization, and a sharp rise in target patient population. These factors have prompted market players to improve and strengthen their current manufacturing and distribution capabilities as well as to focus on product commercialization & upgrades. The in-vitro diagnostics market is segmented on technology, end user, and region/country.
“The PCR segment is expected to hold the largest share of the market in 2020 H1.”
Based on technology, the in-vitro diagnostics market is segmented into PCR, NGS, ELISA, Rapid-tests, clinical chemistry, hematology, hemostasis, urinalysis, microbiology testing, and others. The PCR segment is expected to hold the largest share of the global in-vitro diagnostics industry in 2020 – H1. Factors such as the increasing patient emphasis on effective & early patient screening, continued commercialization of novel COVID screening platforms by major players, early efforts of key players to address supply chain bottlenecks, and easy availability of controls & standards are driving the growth of this segment.
“US to account for the largest share of the in-vitro diagnostics industry in 2020 H1.”
The US is expected to account for the largest share of the in-vitro diagnostics market in 2020 - H1, followed by Europe. This can primarily be attributed to the continuous commercialization of innovative diagnostic products coupled with ongoing advancements in the field of gene & immunoassay based products, the recent discovery of genetic biomarkers & their clinical role in immunoassay testing, supportive government policies & their emphasis on novel product development, and the significant expansion of target patient population.
Breakdown of supply-side primary interviews:
Research Coverage
This report studies the in-vitro diagnostics market based on technology, end user, and region/country. It studies major factors (such as drivers and restraints) affecting the market growth. The report also analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for global leaders. It analyzes micromarkets with respect to individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of market segments with respect to five major regions and their respective major countries.
Key Benefits of Buying the Report
This report focuses on various levels of analysis — industry trends, COVID impact on major technologies, market shares of major global players, which together form basic views. It also analyzes the competitive landscape; major & emerging segments of the in-vitro diagnostics market; and high-growth geographies and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.
The global in-vitro diagnostics market size is expected to be valued at USD 61.0 billion in 2020, growing at a CAGR of 6.5% during 2020-2025. The demand for in-vitro diagnostic products due to the COVID-19 pandemic is expected to increase mainly due to factors such as a sharp rise in market demand for PCR, NGS, serology based rapid-test products, the supportive regulatory landscape for product development & commercialization, and a sharp rise in target patient population. These factors have prompted market players to improve and strengthen their current manufacturing and distribution capabilities as well as to focus on product commercialization & upgrades. The in-vitro diagnostics market is segmented on technology, end user, and region/country.
“The PCR segment is expected to hold the largest share of the market in 2020 H1.”
Based on technology, the in-vitro diagnostics market is segmented into PCR, NGS, ELISA, Rapid-tests, clinical chemistry, hematology, hemostasis, urinalysis, microbiology testing, and others. The PCR segment is expected to hold the largest share of the global in-vitro diagnostics industry in 2020 – H1. Factors such as the increasing patient emphasis on effective & early patient screening, continued commercialization of novel COVID screening platforms by major players, early efforts of key players to address supply chain bottlenecks, and easy availability of controls & standards are driving the growth of this segment.
“US to account for the largest share of the in-vitro diagnostics industry in 2020 H1.”
The US is expected to account for the largest share of the in-vitro diagnostics market in 2020 - H1, followed by Europe. This can primarily be attributed to the continuous commercialization of innovative diagnostic products coupled with ongoing advancements in the field of gene & immunoassay based products, the recent discovery of genetic biomarkers & their clinical role in immunoassay testing, supportive government policies & their emphasis on novel product development, and the significant expansion of target patient population.
Breakdown of supply-side primary interviews:
- By Company Type: Tier 1 (45%), Tier 2 (34%), and Tier 3 (21%)
- By Designation: C-level (47%), Director-level (33%), and Others (20%)
- By Region: North America (35%), Europe (32%), APAC (25%), Latin America (6%), and MEA (2%)
Research Coverage
This report studies the in-vitro diagnostics market based on technology, end user, and region/country. It studies major factors (such as drivers and restraints) affecting the market growth. The report also analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for global leaders. It analyzes micromarkets with respect to individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of market segments with respect to five major regions and their respective major countries.
Key Benefits of Buying the Report
This report focuses on various levels of analysis — industry trends, COVID impact on major technologies, market shares of major global players, which together form basic views. It also analyzes the competitive landscape; major & emerging segments of the in-vitro diagnostics market; and high-growth geographies and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 RESEARCH SCOPE
1.3.1 SEGMENTS COVERED
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 MAJOR MARKET STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.2 PROCEDURE-BASED MARKET ESTIMATION
2.2.3 PRIMARY DATA VALIDATION
2.3 COVID-19 IMPACT ASSESSMENT METHODOLOGY
2.3.1 COVID-19 HEALTH ASSESSMENT
2.3.2 COVID-19 ECONOMIC ASSESSMENT
2.3.3 COVID-19 IMPACT ON THE ECONOMY—SCENARIO ASSESSMENT
2.4 RESEARCH ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 MARKET DYNAMICS
3.3 REGULATORY OVERVIEW
3.3.1 US
3.3.2 EUROPE
3.3.3 CHINA
3.3.4 JAPAN
3.3.5 INDIA
4 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY
4.1 INTRODUCTION
4.2 POLYMERASE CHAIN REACTION
4.2.1 RISING PUBLIC PREFERENCE FOR PERSONALIZED MEDICINE IS EXPECTED TO DRIVE THE MARKET FOR PCR OVER THE NEXT DECADE
4.3 NEXT-GENERATION SEQUENCING
4.3.1 ONGOING SHIFT OF NGS FROM A RESEARCH TOOL TO AN EFFECTIVE DIAGNOSTIC MODALITY—A KEY FACTOR DRIVING GROWTH
4.4 RAPID TESTS
4.4.1 PATIENT PREFERENCE FOR SELF-USE OR POC DIAGNOSTIC PLATFORMS TO DRIVE THE ADOPTION OF RAPID TESTS
4.5 ELISA
4.5.1 RISING USE OF IMMUNOASSAYS IN VARIOUS CLINICAL APPLICATIONS TO DRIVE GROWTH IN THIS MARKET
4.6 MICROARRAYS
4.6.1 GROWING APPLICATION OF MICROARRAYS IN CLINICAL DIAGNOSTICS SUPPORTS MARKET GROWTH
4.7 HEMATOLOGY
4.7.1 CONSOLIDATION OF DIAGNOSTIC LABS (MAINLY IN EUROPE) MAY RESTRAIN MARKET GROWTH TO AN EXTENT
4.8 MICROBIOLOGY
4.8.1 CONTINUOUS COMMERCIALIZATION OF AUTOMATED & COMPACT MICROBIOLOGY TEST PLATFORMS TO SUPPORT GROWTH
4.9 COAGULATION & HEMOSTASIS
4.9.1 CONCERNS RELATED TO PRODUCT STANDARDIZATION AND PREMIUM PRODUCT PRICING MAY RESTRAIN MARKET GROWTH
4.10 CLINICAL CHEMISTRY
4.10.1 CONTINUED DIGITIZATION & INTEGRATION OF DIAGNOSTIC TECHNOLOGIES TO DRIVE GROWTH IN THIS MARKET
4.11 URINALYSIS
4.11.1 REPLACEMENT OF TRADITIONAL PLATFORMS WITH AUTOMATED DEVICES TO DRIVE MARKET GROWTH
4.12 OTHER TECHNOLOGIES
5 IN VITRO DIAGNOSTICS MARKET, BY END USER
5.1 INTRODUCTION
5.2 HOSPITAL-BASED LABORATORIES
5.2.1 HOSPITAL-BASED LABORATORIES HAVE WITNESSED HIGH TEST VOLUMES AND DEMAND FOR SERVICES
5.3 REFERENCE LABORATORIES
5.3.1 GOVERNMENT FOCUS ON CONTAINMENT OF COVID-19 WILL ENSURE GREATER TESTING VOLUMES IN REFERENCE LABORATORIES
5.4 INDEPENDENT LABORATORIES
5.4.1 HIGH TESTING VOLUMES AND GOVERNMENT MANDATES HAVE ENSURED STRONG GROWTH IN THIS SEGMENT
5.5 POINT-OF-CARE & SELF-TESTING
5.5.1 PACE OF MARKET GROWTH TO INCREASE AS NEW AND INNOVATIVE TESTS ARE INTRODUCED IN THE MARKET
5.6 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
5.6.1 INDUSTRY-ACADEMIA COLLABORATIONS ARE A KEY DRIVER FOR MARKET GROWTH
5.7 OTHER END USERS
6 IN VITRO DIAGNOSTICS MARKET, BY REGION
6.1 INTRODUCTION
6.2 US
6.2.1 SUPPORTIVE GOVERNMENT REGULATIONS FOR PRODUCT DEVELOPMENT MAKES THE US A MAJOR MARKET
6.3 GERMANY
6.3.1 STRONG TECHNOLOGICAL CAPABILITIES OF LOCAL PLAYERS IN THE FIELD OF POC TESTING TO DRIVE GROWTH IN THE COUNTRY
6.4 ITALY
6.4.1 INCREASING PREFERENCE FOR MOLECULAR DIAGNOSTICS-BASED TESTING PROCEDURES TO DRIVE GROWTH IN ITALY
6.5 FRANCE
6.5.1 LACK OF REIMBURSEMENTS FOR VARIOUS DIAGNOSTIC TESTS TO RESTRAIN THE MARKET IN FRANCE
6.6 SPAIN
6.6.1 GROWING DEMAND FOR PRENATAL GENETIC SCREENING TO DRIVE GROWTH IN SPAIN
6.7 UK
6.7.1 PREMIUM PRICING OF NOVEL PLATFORMS MAY RESTRICT MARKET GROWTH IN THE UK
6.8 JAPAN
6.8.1 RISING ADOPTION OF MOLECULAR DIAGNOSTICS AND OTHER NOVEL TECHNOLOGIES TO DRIVE GROWTH IN JAPAN
6.9 CHINA
6.9.1 THE DEMAND FOR IVD PRODUCTS IN CHINA WILL MAINLY BE DRIVEN BY SUPPORTIVE GOVERNMENT REGULATIONS
6.10 SOUTH KOREA
6.10.1 RISING INDUSTRY FOCUS ON ORGANIC GROWTH STRATEGIES TO PROPEL THE DEMAND FOR IVD PRODUCTS IN SOUTH KOREA
6.11 INDIA
6.11.1 THE IVD INDUSTRY IN INDIA IS ESTIMATED TO WITNESS SIGNIFICANT GROWTH DUE TO THE LARGE PATIENT POPULATION
6.12 BRAZIL
6.12.1 GROWTH OF THE IVD MARKET IN BRAZIL WILL MAJORLY BE DRIVEN BY SUPPORTIVE GOVERNMENT REGULATIONS
6.13 REST OF THE AMERICAS
6.14 REST OF EUROPE
6.15 REST OF ASIA PACIFIC
6.16 MIDDLE EAST & AFRICA
7 COMPETITIVE LANDSCAPE
7.1 INTRODUCTION
7.2 MARKET SHARE ANALYSIS
7.3 COMPETITIVE SITUATION AND TRENDS
7.3.1 PRODUCT COMMERCIALIZATION AND UPGRADES
7.3.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
7.3.3 EXPANSIONS
7.4 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 RESEARCH SCOPE
1.3.1 SEGMENTS COVERED
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 MAJOR MARKET STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.2 PROCEDURE-BASED MARKET ESTIMATION
2.2.3 PRIMARY DATA VALIDATION
2.3 COVID-19 IMPACT ASSESSMENT METHODOLOGY
2.3.1 COVID-19 HEALTH ASSESSMENT
2.3.2 COVID-19 ECONOMIC ASSESSMENT
2.3.3 COVID-19 IMPACT ON THE ECONOMY—SCENARIO ASSESSMENT
2.4 RESEARCH ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 MARKET DYNAMICS
3.3 REGULATORY OVERVIEW
3.3.1 US
3.3.2 EUROPE
3.3.3 CHINA
3.3.4 JAPAN
3.3.5 INDIA
4 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY
4.1 INTRODUCTION
4.2 POLYMERASE CHAIN REACTION
4.2.1 RISING PUBLIC PREFERENCE FOR PERSONALIZED MEDICINE IS EXPECTED TO DRIVE THE MARKET FOR PCR OVER THE NEXT DECADE
4.3 NEXT-GENERATION SEQUENCING
4.3.1 ONGOING SHIFT OF NGS FROM A RESEARCH TOOL TO AN EFFECTIVE DIAGNOSTIC MODALITY—A KEY FACTOR DRIVING GROWTH
4.4 RAPID TESTS
4.4.1 PATIENT PREFERENCE FOR SELF-USE OR POC DIAGNOSTIC PLATFORMS TO DRIVE THE ADOPTION OF RAPID TESTS
4.5 ELISA
4.5.1 RISING USE OF IMMUNOASSAYS IN VARIOUS CLINICAL APPLICATIONS TO DRIVE GROWTH IN THIS MARKET
4.6 MICROARRAYS
4.6.1 GROWING APPLICATION OF MICROARRAYS IN CLINICAL DIAGNOSTICS SUPPORTS MARKET GROWTH
4.7 HEMATOLOGY
4.7.1 CONSOLIDATION OF DIAGNOSTIC LABS (MAINLY IN EUROPE) MAY RESTRAIN MARKET GROWTH TO AN EXTENT
4.8 MICROBIOLOGY
4.8.1 CONTINUOUS COMMERCIALIZATION OF AUTOMATED & COMPACT MICROBIOLOGY TEST PLATFORMS TO SUPPORT GROWTH
4.9 COAGULATION & HEMOSTASIS
4.9.1 CONCERNS RELATED TO PRODUCT STANDARDIZATION AND PREMIUM PRODUCT PRICING MAY RESTRAIN MARKET GROWTH
4.10 CLINICAL CHEMISTRY
4.10.1 CONTINUED DIGITIZATION & INTEGRATION OF DIAGNOSTIC TECHNOLOGIES TO DRIVE GROWTH IN THIS MARKET
4.11 URINALYSIS
4.11.1 REPLACEMENT OF TRADITIONAL PLATFORMS WITH AUTOMATED DEVICES TO DRIVE MARKET GROWTH
4.12 OTHER TECHNOLOGIES
5 IN VITRO DIAGNOSTICS MARKET, BY END USER
5.1 INTRODUCTION
5.2 HOSPITAL-BASED LABORATORIES
5.2.1 HOSPITAL-BASED LABORATORIES HAVE WITNESSED HIGH TEST VOLUMES AND DEMAND FOR SERVICES
5.3 REFERENCE LABORATORIES
5.3.1 GOVERNMENT FOCUS ON CONTAINMENT OF COVID-19 WILL ENSURE GREATER TESTING VOLUMES IN REFERENCE LABORATORIES
5.4 INDEPENDENT LABORATORIES
5.4.1 HIGH TESTING VOLUMES AND GOVERNMENT MANDATES HAVE ENSURED STRONG GROWTH IN THIS SEGMENT
5.5 POINT-OF-CARE & SELF-TESTING
5.5.1 PACE OF MARKET GROWTH TO INCREASE AS NEW AND INNOVATIVE TESTS ARE INTRODUCED IN THE MARKET
5.6 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
5.6.1 INDUSTRY-ACADEMIA COLLABORATIONS ARE A KEY DRIVER FOR MARKET GROWTH
5.7 OTHER END USERS
6 IN VITRO DIAGNOSTICS MARKET, BY REGION
6.1 INTRODUCTION
6.2 US
6.2.1 SUPPORTIVE GOVERNMENT REGULATIONS FOR PRODUCT DEVELOPMENT MAKES THE US A MAJOR MARKET
6.3 GERMANY
6.3.1 STRONG TECHNOLOGICAL CAPABILITIES OF LOCAL PLAYERS IN THE FIELD OF POC TESTING TO DRIVE GROWTH IN THE COUNTRY
6.4 ITALY
6.4.1 INCREASING PREFERENCE FOR MOLECULAR DIAGNOSTICS-BASED TESTING PROCEDURES TO DRIVE GROWTH IN ITALY
6.5 FRANCE
6.5.1 LACK OF REIMBURSEMENTS FOR VARIOUS DIAGNOSTIC TESTS TO RESTRAIN THE MARKET IN FRANCE
6.6 SPAIN
6.6.1 GROWING DEMAND FOR PRENATAL GENETIC SCREENING TO DRIVE GROWTH IN SPAIN
6.7 UK
6.7.1 PREMIUM PRICING OF NOVEL PLATFORMS MAY RESTRICT MARKET GROWTH IN THE UK
6.8 JAPAN
6.8.1 RISING ADOPTION OF MOLECULAR DIAGNOSTICS AND OTHER NOVEL TECHNOLOGIES TO DRIVE GROWTH IN JAPAN
6.9 CHINA
6.9.1 THE DEMAND FOR IVD PRODUCTS IN CHINA WILL MAINLY BE DRIVEN BY SUPPORTIVE GOVERNMENT REGULATIONS
6.10 SOUTH KOREA
6.10.1 RISING INDUSTRY FOCUS ON ORGANIC GROWTH STRATEGIES TO PROPEL THE DEMAND FOR IVD PRODUCTS IN SOUTH KOREA
6.11 INDIA
6.11.1 THE IVD INDUSTRY IN INDIA IS ESTIMATED TO WITNESS SIGNIFICANT GROWTH DUE TO THE LARGE PATIENT POPULATION
6.12 BRAZIL
6.12.1 GROWTH OF THE IVD MARKET IN BRAZIL WILL MAJORLY BE DRIVEN BY SUPPORTIVE GOVERNMENT REGULATIONS
6.13 REST OF THE AMERICAS
6.14 REST OF EUROPE
6.15 REST OF ASIA PACIFIC
6.16 MIDDLE EAST & AFRICA
7 COMPETITIVE LANDSCAPE
7.1 INTRODUCTION
7.2 MARKET SHARE ANALYSIS
7.3 COMPETITIVE SITUATION AND TRENDS
7.3.1 PRODUCT COMMERCIALIZATION AND UPGRADES
7.3.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
7.3.3 EXPANSIONS
7.4 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 IMPACT OF COVID-19 ON THE IN VITRO DIAGNOSTICS MARKET AND OVERALL MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, CHALLENGES
TABLE 2 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES
TABLE 3 EUROPE: CLASSIFICATION OF IVD DEVICES
TABLE 4 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 5 IN VITRO DIAGNOSTICS MARKET FOR PCR, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 6 IN VITRO DIAGNOSTICS MARKET FOR NGS, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 7 IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 8 IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 9 IN VITRO DIAGNOSTICS MARKET FOR MICROARRAY, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 10 IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 11 IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 12 IN VITRO DIAGNOSTICS MARKET FOR COAGULATION AND HEMOSTASIS, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 13 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 14 IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 15 IN VITRO DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 16 GLOBAL IN VITRO DIAGNOSTIC MARKET, BY END USER, 2019-2025 (USD MILLION)
TABLE 17 IN VITRO DIAGNOSTICS MARKET FOR HOSPITAL-BASED LABORATORIES, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 18 IN VITRO DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 19 IN VITRO DIAGNOSTICS MARKET FOR INDEPENDENT LABORATORIES, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 20 IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE & SELF TESTING, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 21 IN VITRO DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 22 IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 23 IN VITRO DIAGNOSTICS MARKET, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 24 US: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 25 US: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 26 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 27 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 28 ITALY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 29 ITALY: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 30 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 31 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 32 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 33 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 34 UK: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 35 UK: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 36 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 37 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 38 CHINA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 39 CHINA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 40 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 41 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 42 INDIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 43 INDIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 44 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 45 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 46 REST OF AMERICAS: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 47 REST OF AMERICAS: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 48 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 49 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 50 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 51 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 54 PRODUCT COMMERCIALIZATION AND UPGRADES (DECEMBER 2019–APRIL 2020)
TABLE 55 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
(DECEMBER 2019–APRIL 2020)
TABLE 56 EXPANSIONS (DECEMBER 2019–APRIL 2020)
TABLE 1 IMPACT OF COVID-19 ON THE IN VITRO DIAGNOSTICS MARKET AND OVERALL MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, CHALLENGES
TABLE 2 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES
TABLE 3 EUROPE: CLASSIFICATION OF IVD DEVICES
TABLE 4 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 5 IN VITRO DIAGNOSTICS MARKET FOR PCR, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 6 IN VITRO DIAGNOSTICS MARKET FOR NGS, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 7 IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 8 IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 9 IN VITRO DIAGNOSTICS MARKET FOR MICROARRAY, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 10 IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 11 IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 12 IN VITRO DIAGNOSTICS MARKET FOR COAGULATION AND HEMOSTASIS, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 13 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 14 IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 15 IN VITRO DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 16 GLOBAL IN VITRO DIAGNOSTIC MARKET, BY END USER, 2019-2025 (USD MILLION)
TABLE 17 IN VITRO DIAGNOSTICS MARKET FOR HOSPITAL-BASED LABORATORIES, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 18 IN VITRO DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 19 IN VITRO DIAGNOSTICS MARKET FOR INDEPENDENT LABORATORIES, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 20 IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE & SELF TESTING, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 21 IN VITRO DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 22 IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 23 IN VITRO DIAGNOSTICS MARKET, BY COUNTRY/REGION, 2019–2025 (USD MILLION)
TABLE 24 US: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 25 US: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 26 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 27 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 28 ITALY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 29 ITALY: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 30 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 31 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 32 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 33 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 34 UK: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 35 UK: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 36 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 37 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 38 CHINA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 39 CHINA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 40 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 41 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 42 INDIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 43 INDIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 44 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 45 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 46 REST OF AMERICAS: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 47 REST OF AMERICAS: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 48 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 49 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 50 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 51 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 54 PRODUCT COMMERCIALIZATION AND UPGRADES (DECEMBER 2019–APRIL 2020)
TABLE 55 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
(DECEMBER 2019–APRIL 2020)
TABLE 56 EXPANSIONS (DECEMBER 2019–APRIL 2020)
LIST OF FIGURES
FIGURE 1 IN VITRO DIAGNOSTICS: OVERALL INDUSTRY ECOSYSTEM
FIGURE 2 MAJOR SECONDARY SOURCES
FIGURE 3 BREAKDOWN OF PRIMARIES: IN VITRO DIAGNOSTICS MARKET
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 5 MARKET SIZE ESTIMATION: GLOBAL IN VITRO DIAGNOSTICS MARKET
FIGURE 6 COVID-19: THE GLOBAL PROPAGATION
FIGURE 7 COVID-19 PROPAGATION: SELECT COUNTRIES
FIGURE 8 COUNTRIES BEGIN WITH SIMILAR TRAJECTORIES BUT CURVES DEVIATE
BASED ON MEASURES TAKEN
FIGURE 9 REVISED GDP FORECASTS FOR SELECT G20 COUNTRIES IN 2020
FIGURE 10 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 11 SCENARIO IN TERMS OF RECOVERY OF THE GLOBAL ECONOMY
FIGURE 12 IN VITRO DIAGNOSTICS MARKET: KEY SEGMENTS WITH COVID-19 IMPACT
FIGURE 13 US: REGULATORY PROCESS FOR IVD DEVICES
FIGURE 14 EUROPE: REGULATORY PROCESS FOR IVD DEVICES
FIGURE 15 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
FIGURE 16 INDIA: REGULATORY PROCESS FOR IVD DEVICES
FIGURE 17 IN VITRO DIAGNOSTICS MARKET SHARE ANALYSIS: TOP 5 GLOBAL PLAYERS (2019)
FIGURE 1 IN VITRO DIAGNOSTICS: OVERALL INDUSTRY ECOSYSTEM
FIGURE 2 MAJOR SECONDARY SOURCES
FIGURE 3 BREAKDOWN OF PRIMARIES: IN VITRO DIAGNOSTICS MARKET
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 5 MARKET SIZE ESTIMATION: GLOBAL IN VITRO DIAGNOSTICS MARKET
FIGURE 6 COVID-19: THE GLOBAL PROPAGATION
FIGURE 7 COVID-19 PROPAGATION: SELECT COUNTRIES
FIGURE 8 COUNTRIES BEGIN WITH SIMILAR TRAJECTORIES BUT CURVES DEVIATE
BASED ON MEASURES TAKEN
FIGURE 9 REVISED GDP FORECASTS FOR SELECT G20 COUNTRIES IN 2020
FIGURE 10 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 11 SCENARIO IN TERMS OF RECOVERY OF THE GLOBAL ECONOMY
FIGURE 12 IN VITRO DIAGNOSTICS MARKET: KEY SEGMENTS WITH COVID-19 IMPACT
FIGURE 13 US: REGULATORY PROCESS FOR IVD DEVICES
FIGURE 14 EUROPE: REGULATORY PROCESS FOR IVD DEVICES
FIGURE 15 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
FIGURE 16 INDIA: REGULATORY PROCESS FOR IVD DEVICES
FIGURE 17 IN VITRO DIAGNOSTICS MARKET SHARE ANALYSIS: TOP 5 GLOBAL PLAYERS (2019)
